Genital infections in high-risk human papillomavirus positive Paraguayan women aged 30-64 with and without cervical lesions.
Humans
Female
Adult
Middle Aged
Papillomavirus Infections
/ epidemiology
Cross-Sectional Studies
Paraguay
/ epidemiology
Uterine Cervical Neoplasms
/ epidemiology
Prevalence
Uterine Cervical Dysplasia
/ epidemiology
Papillomaviridae
/ isolation & purification
Sexually Transmitted Diseases
/ epidemiology
Human Papillomavirus Viruses
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
03
04
2024
accepted:
16
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
To determine the prevalence of genital infections (GIs), including sexual transmitted STIs: Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, and opportunistic pathogens that generally do not cause STIs, non-classic STI: Ureaplasma urealyticum, Ureaplasma parvum and Mycoplasma hominis, in women with high-risk oncogenic human papillomavirus (hr-HPV) infection and their association with cervical lesions. A cross-sectional study was carried out including 231 hr-HPV positive women. Of these, 46 has histologically confirmed cervical intraepithelial neoplasia 3 (CIN3) or more (including CIN3 and cervical cancer lesions-CIN3+). GIs were detected by multiplex real time PCR. Odds ratios (OR) were estimated to explore possible associations between GIs and the presence or absence of CIN3+ lesions. Additionally, we examined associations between sociodemographic, sexual, and clinical characteristics and the presence of GIs. In total, there were 174/231 cases of GIs corresponding to an overall prevalence of 75.3% (95%CI: 69.4-80.4), being non-classic STIs the most common (72.3%) compared to STIs (12.6%). The most prevalent non-classic STI and STI were U. parvum (49.8%) and C. trachomatis (7.4%), respectively. The odds of presenting GIs were 3 times higher in women under 46 years compared to older counterparts (OR: 3.32, 95%CI: 1.74-6.16), and in women with a normal Pap smear with inflammation compared to those without inflammation (OR: 3.31, 95%CI: 1.15-9.77). GIs were equally present in women with and without CIN3+ lesions. We observed an association of GIs with inflammation in the Pap smear, but no association with CIN3+, as some of them are very common and likely part of the normal vaginal flora, suggesting that such infections do not appear to be cofactors in cervical carcinogenesis, although larger prospective studies are needed.
Identifiants
pubmed: 39471231
doi: 10.1371/journal.pone.0312947
pii: PONE-D-24-11814
pmc: PMC11521256
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0312947Informations de copyright
Copyright: © 2024 Arévalos et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Int J Cancer. 2000 Jan 1;85(1):35-9
pubmed: 10585579
Front Microbiol. 2020 May 05;11:827
pubmed: 32431682
Trop Med Int Health. 2003 Jul;8(7):595-603
pubmed: 12828541
J Family Reprod Health. 2013 Mar;7(1):23-7
pubmed: 24971098
Rev Inst Med Trop Sao Paulo. 2021 Jan 20;63:e1
pubmed: 33503149
PLoS One. 2023 Jun 23;18(6):e0287633
pubmed: 37352297
Clin Microbiol Infect. 2021 Aug;27(8):1083-1095
pubmed: 33975008
PLoS One. 2018 Nov 29;13(11):e0207853
pubmed: 30496244
BMC Public Health. 2014 Dec 05;14:1248
pubmed: 25476713
Front Reprod Health. 2022 Jul 28;4:887736
pubmed: 36303664
Microbiome. 2016 Nov 1;4(1):58
pubmed: 27802830
J Gynecol Oncol. 2016 Sep;27(5):e49
pubmed: 27329197
Cancers (Basel). 2020 Apr 28;12(5):
pubmed: 32353967
CA Cancer J Clin. 2024 May-Jun;74(3):229-263
pubmed: 38572751
PLoS One. 2013;8(1):e54022
pubmed: 23308295
Front Cell Infect Microbiol. 2023 Mar 16;13:1145215
pubmed: 37009504
Lancet. 2024 Aug 3;404(10451):435-444
pubmed: 39097395
Front Reprod Health. 2022 Dec 06;4:992176
pubmed: 36560972
Infect Agent Cancer. 2014 Sep 08;9:30
pubmed: 25621003
Infect Dis Obstet Gynecol. 2013;2013:184302
pubmed: 24204103
Cureus. 2022 Jan 17;14(1):e21331
pubmed: 35186589
Microorganisms. 2023 Mar 06;11(3):
pubmed: 36985236
Lancet Reg Health Am. 2023 Sep 20;26:100593
pubmed: 37766799
J Clin Outcomes Manag. 2014 Jan;21(1):30-38
pubmed: 25554725
Int J Infect Dis. 2014 Aug;25:16-21
pubmed: 24818991
PLoS One. 2019 Jun 27;14(6):e0218016
pubmed: 31246959
J Infect Chemother. 2017 Dec;23(12):814-819
pubmed: 28923300
J Natl Cancer Inst. 2006 Mar 1;98(5):303-15
pubmed: 16507827
Int J Cancer. 2006 Sep 1;119(5):1108-24
pubmed: 16570271
Virol J. 2022 Jul 29;19(1):127
pubmed: 35906702
Immunity. 2015 May 19;42(5):965-76
pubmed: 25992865
Am J Cancer Res. 2016 Jun 01;6(6):1371-83
pubmed: 27429850
Infect Agent Cancer. 2017 Jan 6;12:3
pubmed: 28074107
PLoS One. 2016 Apr 26;11(4):e0153274
pubmed: 27115350
Virus Res. 2002 Nov;89(2):191-9
pubmed: 12445659
Int J Cancer. 1994 Feb 1;56(3):358-63
pubmed: 8314322
Int J Infect Dis. 2015 Oct;39:44-9
pubmed: 26283550
Int J Cancer. 2007 Feb 15;120(4):885-91
pubmed: 17131323
Can J Infect Dis Med Microbiol. 2020 Aug 30;2020:7640758
pubmed: 32908620
Int J Cancer. 2004 Sep 1;111(3):431-9
pubmed: 15221973
PLoS One. 2017 Jan 23;12(1):e0170189
pubmed: 28114325
BMJ Open. 2020 May 24;10(5):e035796
pubmed: 32448795
Sex Transm Dis. 2003 Jul;30(7):575-80
pubmed: 12838087
Microbes Infect. 2009 Apr;11(4):435-42
pubmed: 19397882
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):657-64
pubmed: 26810061